核药是目前的热点,...查看全文
Cellectar(CLRB)02-15 05:35
$Cellectar(CLRB)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0001104659-24-023800 Act: 34 Size: 170 KB 网页链接查看全文
Cellectar(CLRB)02-15 05:55
$Cellectar(CLRB)$ SC 13G Statement of acquisition of beneficial ownership by individuals Accession Number: 0001104659-24-023902 Act: 34 Size: 52 KB 网页链接查看全文
Cellectar(CLRB)02-15 04:25
$Cellectar(CLRB)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0000935836-24-000191 Act: 34 Size: 30 KB 网页链接查看全文
Cellectar(CLRB)03-27 18:35
$Cellectar(CLRB)$ 10-K Annual report [Section 13 and 15(d), not S-K Item 405] Accession Number: 0001410578-24-000307 Act: 34 Size: 6 MB 网页链接查看全文
Cellectar(CLRB)03-27 18:55
$Cellectar(CLRB)$ 8-K Current report, items 2.02 and 9.01 Accession Number: 0001104659-24-039341 Act: 34 Size: 277 KB 网页链接查看全文
Cellectar(CLRB)04-26 08:05
$Cellectar(CLRB)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0001622627-24-000028 Act: 34 Size: 111 KB 网页链接查看全文
Cellectar(CLRB)04-27 05:05
$Cellectar(CLRB)$ ARS Annual Report to Security Holders Accession Number: 0001104659-24-053062 Act: 34 Size: 658 KB 网页链接查看全文
Cellectar(CLRB)02-15 09:35
$Cellectar(CLRB)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0001622627-24-000007 Act: 34 Size: 109 KB 网页链接查看全文
Cellectar(CLRB)02-08 08:05
$Cellectar(CLRB)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0001493152-24-005340 Act: 34 Size: 96 KB 网页链接查看全文
美股滚雪球03-27 22:00
$Cellectar(CLRB)$ 今天发布了财报,此前发布的iopofosine I 131治疗Waldenstrom’s macroglobulinemia (WM)的三期数据不错,预计在下半年递交NDA,二季度也有研发更新;公司还有核药新型α -释放磷脂放射治疗偶联物CLR 121255,目前用于胰腺癌的治疗,尚处于临床前阶段。
核药是目前的热点,...查看全文
市场调研报告2022-12-16 16:56
据恒州诚思调研统计,2021年全球儿科肿瘤治疗市场规模约 亿元,2017-2021年年复合增长率CAGR约为 %,预计未来将持续保持平稳增长的态势,到2028年市场规模将接近 亿元,未来六年CAGR为 %。
本文调研和分析全球儿科肿瘤治疗发展现状及未来趋势,核心内容如下:
(1)全球市场总体规模,按收...查看全文
市场调研报告2022-12-16 16:54
本文调研和分析全球儿科肿瘤治疗发展现状及未来趋势,核心内容如下:
(1)全球市场儿科肿瘤治疗总体规模,按收入进行了统计分析,历史数据2017-2021年,预测数据2022至2028年。
(2)全球市场竞争格局,全球市场头部企业儿科肿瘤治疗市场占有率及排名,数据2017-2021年。
(3)中国市...查看全文
牛唐2020-12-24 11:26
医药板块速评(2020.12.23)
1、$Athenex(ATNX)$ 口服紫杉醇审批在即,可否参与投资?
2、$Cellectar(CLRB)小而美意外增发,可否迎来抄底良机?
3、$INmune Bio(INMB)阿尔海默兹药物数据发布在即,能否小赌怡情?
$香雪制药(SZ300147)$ $阿里巴巴-SW(09988)$查看全文
$Cellectar Biosciences, Inc.(CLRB)$ DEF 14A - Other definitive proxy statements Filed: 2018-04-23 AccNo: 0001144204-18-021824 Size: 564 KB 网页链接
$Cellectar Biosciences, Inc.(CLRB)$ 8-K - Current report Filed: 2018-04-17 AccNo: 0001144204-18-020927 Size: 29 KBItem 7.01: Regulation FD DisclosureItem 9.01: Financial Statements and Exhibits 网页链接
$Cellectar Biosciences, Inc.(CLRB)$ 8-K - Current report Filed: 2018-04-16 AccNo: 0001144204-18-020713 Size: 29 KBItem 7.01: Regulation FD DisclosureItem 9.01: Financial Statements and Exhibits 网页链接
$Cellectar Biosciences, Inc.(CLRB)$ 8-K - Current report Filed: 2018-04-16 AccNo: 0001144204-18-020713 Size: 29 KBItem 7.01: Regulation FD DisclosureItem 9.01: Financial Statements and Exhibits 网页链接
$Cellectar Biosciences, Inc.(CLRB)$ 8-K - Current report Filed: 2018-04-16 AccNo: 0001144204-18-020710 Size: 29 KBItem 7.01: Regulation FD DisclosureItem 9.01: Financial Statements and Exhibits 网页链接
$Cellectar Biosciences, Inc.(CLRB)$ 8-K - Current report Filed: 2018-04-16 AccNo: 0001144204-18-020710 Size: 29 KBItem 7.01: Regulation FD DisclosureItem 9.01: Financial Statements and Exhibits 网页链接
$Cellectar Biosciences, Inc.(CLRB)$ PRE 14A - Other preliminary proxy statements Filed: 2018-04-13 AccNo: 0001144204-18-020529 Size: 565 KB 网页链接
$Cellectar Biosciences, Inc.(CLRB)$ 8-K - Current report Filed: 2018-04-04 AccNo: 0001144204-18-019222 Size: 57 KBItem 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain OfficersItem 9...
$Cellectar Biosciences, Inc.(CLRB)$ 8-K - Current report Filed: 2018-04-04 AccNo: 0001144204-18-019051 Size: 28 KBItem 7.01: Regulation FD DisclosureItem 9.01: Financial Statements and Exhibits 网页链接
$Cellectar Biosciences, Inc.(CLRB)$ 8-K - Current report Filed: 2018-03-27 AccNo: 0001144204-18-017159 Size: 27 KBItem 7.01: Regulation FD DisclosureItem 9.01: Financial Statements and Exhibits 网页链接